NCT07907432Not yet recruiting
Serum Treg/Th17-Related Cytokines and Systemic Inflammatory Indices in Differentiated Thyroid Cancer
Treg/Th17-Related Cytokine Profile and Systemic Inflammatory Indices in Differentiated Thyroid Cancer: Relationship With Clinicopathological Features
Source: ClinicalTrials.gov · Last updated 2 Nov 2026
Brief summary (registry, in English)
This study measures circulating immune-signaling molecules before thyroid surgery to determine whether they differ between patients whose thyroid nodule proves to be a differentiated thyroid carcinoma and patients whose nodule proves to be benign. Adults scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter are enrolled consecutively before surgery, while the nature of the nodule is still unknown. One additional blood tube is obtained during the routine preoperative blood sampling that is performed for every patient on the day of hospital admission, one day before surgery. No separate venipuncture, no additional test, no additional visit and no change to diagnosis, treatment or follow-up is involved. Serum interleukin-17A, measured before surgery, is the primary outcome measure. Additional Treg/Th17-related cytokines, the interleukin-17A to interleukin-10 ratio, and systemic inflammatory indices calculated from the same blood draw are secondary outcome measures. Participants are assigned to the differentiated thyroid cancer group or the benign nodular goiter group after surgery, on the basis of the final histopathology report.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 90 (estimated)
- First submitted
- 25 Oct 2026
- Start date
- 1 Nov 2026
- Primary completion date
- 31 Aug 2027
- Lead sponsor
- Marmara University
- Diseases
- Thyroid cancer
- NCT number
- NCT07907432
What you commit to
- Study type: Observational
- Planned participants: 90
- From 1 Nov 2026 to the primary completion date, 31 Aug 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of immunosuppressive or systemic corticosteroid therapy
Other illness
- Graves disease, toxic multinodular goiter, toxic adenoma, or hyperthyroidism of any cause
- Active infection
- Any active non-thyroid malignancy
- Systemic autoimmune or inflammatory disease other than Hashimoto thyroiditis
Other
- Pregnancy
Who the study is looking for
- Age 18 to 75 years
- Scheduled for elective thyroidectomy for a thyroid nodule or nodular goiter
- Euthyroid, defined as thyroid stimulating hormone and free thyroxine within the laboratory reference range on the day of blood sampling
- Written informed consent
- Final histopathology of differentiated thyroid carcinoma of papillary, follicular or oncocytic type (case group), or of benign nodular goiter (control group)
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Marmara University School of Medicine Hospital, Department of General Surgery Coordinator of this site? Confirm its status | Istanbul | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.